
At its meeting in April, the European Medicines Agency’s (EMA) expert committee, the CHMP, has given a positive opinion on four drugs for European use, and has recommended extensions to the indications of an additional seven medicines.
The Committee for Medicinal Products for Human Use has given its regulatory thumbs-up to British firm Amryt Pharmaceuticals, which was seeking the committee’s approval for drug Filsuvez (birch bark extract) for the treatment of epidermolysis bullosa, a group of rare diseases that cause blistering skin and can be fatal in the most severe cases.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app